View Future GrowthOptimi Health 과거 순이익 실적과거 기준 점검 0/6Optimi Health은 연평균 15.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.4%의 비율로 증가했습니다. 매출은 연평균 31.8%의 비율로 증가했습니다.핵심 정보15.84%순이익 성장률27.50%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률31.82%자기자본이익률-79.87%순이익률-2,069.73%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 21hOptimi Health Corp Advances Highest-Purity Natural Psilocybin ExtractOptimi Health Corp. announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical psilocybin extract produced by the Company to date. The milestone reflects sustained gains across Optimi's cultivation program. Drawing on a proprietary library of more than 200 distinct mushroom genetics maintained at the Company's facilities, Optimi has selectively advanced cultivars demonstrating increasingly elevated psilocybin content. Those cultivation improvements, combined with refinements to the Company's extraction process, have produced a botanical extract substantially more concentrated than prior production cycles while maintaining its naturally derived profile. A portion of the completed extract has been earmarked to support upcoming clinical research programs in Europe, where Optimi is expected to supply GMP-grade finished material into sponsor-led studies. Consistent with the Company's role as a regulated manufacturer rather than a drug-development sponsor, Optimi's contribution is the supply of psilocybin-containing finished drug products. Remaining biomass from the psilocybin production cycle will be retained at Optimi's facilities for ongoing product development, formulation refinement, and future regulated supply initiatives as international access pathways continue to expand. The milestone also reinforces Optimi's commercial supply in Australia, where the Company's naturally derived 5 mg psilocybin capsules are being prescribed for treatment-resistant depression under the Therapeutic Goods Administration's Authorised Prescriber Scheme. The higher-purity extract strengthens the material base supporting that supply. Optimi remains among a small number of commercial-stage companies worldwide whose psilocybin drug products are reaching patients through reimbursed treatment pathways, with eligible Australian patients accessing psilocybin-assisted therapy for treatment-resistant depression supported by established reimbursement initiatives. Aggregated data published in connection with Australia's Authorised Prescriber Scheme, under which Optimi has supplied psilocybin finished products since September 2025, indicate that no serious adverse events have been reported among patients treated with psilocybin under the Scheme as of December 2025.New Risk • May 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 75% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Revenue is less than US$1m (CA$194k revenue, or US$141k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$33.5m market cap).Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Jason Mosberian was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 20Optimi Health Corp. has completed a Follow-on Equity Offering in the amount of $15 million.Optimi Health Corp. has completed a Follow-on Equity Offering in the amount of $15 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,400,000 Price\Range: $6.25 Discount Per Security: $0.47 Transaction Features: New Market Listing공시 • Jan 27Optimi Health Completes First 2026 Production of MDMA and Psilocybin CapsulesOptimi Health Corp. reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 naturally derived psilocybin capsules in a 5 mg dosage form. Final packaging, labelling, and batch release were completed in accordance with Optimi's Drug Establishment Licence issued by Health Canada. The capsules are GMP-compliant and supported by Certificates of Analysis confirming conformance with applicable quality specifications, following receipt of the required Australian import permits. Post-Traumatic Stress Disorder (PTSD) and Treatment-Resistant Depression (TRD) represent significant unmet medical needs in Australia. National data published by the Australian Bureau of Statistics indicate that approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people. According to the Australian Institute of Health and Welfare, more than 1.3 million Australians are affected by depressive disorders, and clinical research suggests that around one-third of individuals with major depressive disorder do not respond adequately to standard treatments.공시 • Dec 20Optimi Health Corp. Announces Board ChangesOptimi Health Corp. has appointed Mr. Jason Mosberian as a director of the Company, effective 18 December 2025. Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in public practice for 6 years. He currently serves as Senior Vice President and Partner at BFL Canada and has over a decade of experience providing tailored risk management and insurance solutions to clients in various industries, including manufacturing, distribution and life sciences. Mr. Mosberian replaces Mr. Jonathan Schintler on the Company's Board of Directors. Mr. Mosberian's appointment is subject to the approval of the Canadian Securities Exchange.공시 • Sep 06Optimi Health Corp. has filed an IPO in the amount of $27.0125 million.Optimi Health Corp. has filed an IPO in the amount of $27.0125 million. Security Name: Common Shares Security Type: Common Stock공시 • Jul 30Optimi Health Corp., Annual General Meeting, Sep 08, 2025Optimi Health Corp., Annual General Meeting, Sep 08, 2025. Location: unit 600, 21 water street, british columbia, v6b 1a1, vancouver Canada공시 • Jul 20Optimi Health Corp. announced that it expects to receive CAD 3.45 million in fundingOptimi Health Corp. announces a non-brokered private placement to issue 3,450 unsecured convertible debentures at a price of CAD 1,000 per Convertible Debenture for gross proceeds of CAD 3,450,000 on July 18, 2025. The Convertible Debentures will bear interest at a rate of 15% per annum. The principal amount of each Convertible Debenture will be convertible into common shares of the Company at a conversion price of CAD 0.15, being the closing price of the Common Shares on the Canadian Securities Exchange preceding the execution by each Investor of the subscription agreement for the Convertible Debentures. All securities issued under the Offering, including securities issuable on conversion thereof, will be subject to a hold period expiring four months and a day from the date of issuance, in accordance with the rules and policies of the CSE and applicable Canadian securities laws. The Offering is expected to close on or about July 24, 2025공시 • Mar 12Optimi Health Corp. announced a financing transactionOptimi Health Corp. announced a private placement that it will issue 100,000 common shares of the company at a deemed price per share to receive funding on March 12, 2025. The shares will be subject to a hold period of four months and one day from the date of issuance. Additionally, the Company is settling CAD 20,000 in outstanding service fees by issuing common shares at a deemed price per share equal to the closing price on the CSE on the last trading day prior to issuance. The transaction is expected to close on or around March 19, 2025.공시 • Feb 01Optimi Health Corp. Completes Larger MDMA Capsule Batch to Date, Expands Stability ProgramOptimi Health Corp. has completed its larger production batch of MDMA to date—over 4,000 GMP capsules, enough to treat more than 1,000 patients. As part of its commitment to ensuring long-term product stability and quality, Optimi has also completed one year of stability data on previously manufactured MDMA capsules, validating a one-yearshelf life and extending the usability of its existing inventory for clinical and therapeutic applications. Additionally, the company has initiated a two-yearstability program to further validate the long-term quality and reliability of its MDMA capsules. With a growing number of authorized physicians prescribing Optimi's MDMA for PTSD in Australia, increasing demand for Special Access Program (SAP) requests in Canada, and a key Phase 2 clinical trial initiative for PTSD in Israel, Optimi is one of the few companies able to both manufacture its psychedelic drugs in-house and export cost-effective, GMP-grade MDMA capsules globally.공시 • Jan 31Optimi Health Corp. Auditor Raises 'Going Concern' DoubtOptimi Health Corp. filed its Annual on Jan 29, 2025 for the period ending Sep 30, 2024. In this report its auditor, Davidson & Company, gave an unqualified opinion expressing doubt that the company can continue as a going concern.공시 • Jan 29Optimi Health Corp. announced that it has received CAD 0.9735 million in fundingOn January 28, 2025. Optimi Health Corp has closed the transaction. it has issued 1,316,668 Units at a price of CAD 0.30 per unit for gross proceeds of CAD 395,000.14 in its second tranche. total Offering raise to CAD 934,000.공시 • Jan 16Optimi Health Corp. Reports First Patients Dosed in Landmark Natural Psilocybin Study in New ZealandOptimi Health Corp. announced that its natural psilocybin extract has been successfully exported to New Zealand. The shipment has enabled the dosing of the first participants using Optimi's natural psilocybin extract in a groundbreaking clinical trial supported by Tu Wairua, and the Matai Medical Research Institute, based in Gisborne, New Zealand. The study is the first of its kind, combining indigenous Maori knowledge systems (matauranga Maori) with cutting-edge clinical methodologies to address methamphetamine addiction. The inaugural cohort of participants has completed preparatory sessions and received psilocybin-assisted therapy in a culturally grounded, marae-based setting using Optimi's natural p silocybin extract. Key Highlights. First Participants Dosed: Optimi's natural psilocbin extract was administered to participants at Rangiwaho Marae, marking a historic step in combining traditional healing frameworks with modern therapeutic approaches. Innovative Collaboration. The Tu Wairua initiative unites indigenous leaders, health researchers, and industry partners, including Rua Bioscience and the Institute of Environmental Science and Research (ESR), to explore the therapeutic potential of taonga (mushroom) varieties. Cultural Integration. The trial emphasizes tikanga (cultural protocols) and collective reflection to ensure the safety, feasibility, and long-term well-being of participants and their communities. Supporting Indigenous Leadership in Psychedelic Therapies. Building a Framework for Global Psychedelic Innovation. The study, supported by Rua Bioscience and other New Zealand-based organizations, is a testament to the global collaboration required to advance psychedelic medicine responsibly. Optimi's involvement underscores the Company's mission to make high-quality, natural psilocybin accessible to researchers and patients worldwide. Learnings from this clinical trial will inform future trial phases and contribute to the broader understanding of psilocybin-assisted therapies.공시 • Oct 24Optimi Health Corp. Announces First PTSD Patients Treated with MDMA Capsules in AustraliaOptimi Health Corp. announced that the first group of patients with post-traumatic stress disorder (PTSD) in Australia has successfully received treatment with its GMP-certified MDMA capsules under the Authorised Prescriber Scheme. In response to growing demand, the Company has received an additional order for 700 doses after its initial shipment of 160 doses was fully allocated in under eight weeks. First Patient Dosing: Patients in Australia are being treated with Optimi's GMP-certifiedMD capsules for PTSD, positioning Optimi as one of the few companies with in-market products actively treating real patients. Additional Orders: An additional 700 doses of MDMA capsules have been ordered to meet demand after the initial 160 doses were fully allocated in less than eight weeks. Real World Data: The Patient Reported Outcomes (PROs) being gathered through the patient registry at Australian National University will provide data on the effectiveness of MDMA treatments across a diverse range of Australian patients. The data collected from thousands of patients using Optimi's MDMA will be one of the most comprehensive and valuable data sets in the history of psychedelic-assisted therapies. Optimi's close collaboration with Mind Medicine Australia-a leading non-profit focused on expanding access to psychedelic-assisted therapies-has been instrumental in bringing these treatments to market. Mind Medicine Australia advocates for the safe integration of psychedelics into mental health treatments and has been a key partner in connecting Optimi's MDMA with Australian healthcare providers.공시 • Oct 21Optimi Health Corp. Announces Chief Executive Officer ChangesOptimi Health Corp. announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons. Effective October 21, 2024, the Board has appointed Mr. Dane Stevens, Co-Founder of Optimi, as Interim Chief Executive Officer. In this role, Mr. Stevens will continue to advance the Company's key initiatives, with a focus on business development, expanding revenue opportunities, and maintaining the Company's strategic direction.공시 • Aug 08Optimi Health Corp. announced that it expects to receive CAD 5 million in fundingOptimi Health Corp. announced a non brokered private placement of up to 16,666,666 units at an issue price of CAD 0.30 per unit for the gross proceeds of CAD 4,999,999.8 on August 7, 2024. Each Unit comprised of one common share and one-half of one transferable Common Share purchase warrant. Each Warrant entitles the holder to acquire one Common Share at CAD 0.40 for two years from the date of issuance. It is anticipated that insiders of the Company may participate in the Offering for up to CAD 500,000. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws. In connection with the Offering the Company may pay, to qualified non-related parties, a finder’s fee in cash equal to 4% of the gross proceeds raised.공시 • May 15Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp CapsulesOptimi Health Corp. announced it has received a Certificate of Analysis (COA) from independent third-party laboratory testing, confirming that Optimi’s formulated MDMA meets Good Manufacturing Practice (GMP) specifications. Optimi has also completed GMP process validation for the encapsulation of the active pharmaceutical ingredient (API) in both 40mg and 60mg dosage formats for batch sizes up to 1,000 capsules during GMP production. The COA for the finished product affirms important data and analytics around content uniformity, microbial and water content, and dosage strength. Additionally, Optimi’s ongoing stability testing demonstrated that the MDMA API used to make both dosages remains stable within the capsules under both real-time and accelerated storage conditions for up to three months. The MDMA API used to produce the releasable GMP capsules has a purity level of 99.95%.공시 • May 10Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic ResearchOptimi Health Corp. reported a significant update to its collaboration with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV. With the Export Permit confirmed, Optimi will be one of the first psychedelics pharmaceutical manufacturers to ship MDMA to the country.공시 • Apr 16Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical IngredientOptimi Health Corp. has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence. Optimi employed the precursor 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) to guarantee the quality and uniformity of the MDMA API manufacturing process. The production of this MDMA API was produced in-house, explicitly for the recently disclosed supply agreement with the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel.공시 • Apr 02Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin ExtractOptimi Health Corp. announced that three validation batches of its Natural Psilocybin Extract have undergone full release testing and have been issued the Certificate of Analysis (COA) by a third-party, confirming compliance with Good Manufacturing Practice (GMP) specifications. Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats. The third-party COA confirms critical information regarding potency, water content, microbial content, and heavy metal content, ensuring that the Natural Psilocybin Extract meets the predetermined specifications. The completion of both extract validation and finished product testing aligns with Optimi's goal of advancing the drug candidate, marking significant progress toward its eventual release for human consumption. After six months of accelerated data collection, Optimi confirms that its Natural Psilocybin Extract maintained its original potency level without any degradation during stability testing. Furthermore, the Psilocybe cubensis mushrooms used in creating the extract were cultivated in-house under Good Agricultural Collection Practice (GACP) conditions. As the Company prepares to meet its Australian supply commitments with Mind Medicine Australia, Karina Lahnakoski, Optimi's Director of Quality and Commercial Strategies, assures patients and therapists of the reliability and quality of Optimi's drug candidates. Dedicated to fostering collaborations and advancing the scientific understanding of the potential therapeutic benefits of psilocybin, Optimi welcomes inquiries from principal investigators and research groups interested in learning more about the Company’s validated GMP Natural Psilocybin Extract and other drug candidates.공시 • Feb 10Optimi Health Corp. announced that it expects to receive CAD 1.5 million in fundingOptimi Health Corp announces non-brokered private placement of 5,000,000 units at an issue price of CAD 0.30 per Unit for gross proceeds of CAD 1,500,000 on February 8, 2024. Each unit consists of one common share and one half of one transferable Common Share purchase warrant. Each Warrant entitles the holder to acquire one (1) Common Share at CAD 0.40 for two (2) years from the date of issuance. the transaction include participation from insiders for CAD 605,000. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.공시 • Dec 23Optimi Health Corp., Annual General Meeting, Feb 22, 2024Optimi Health Corp., Annual General Meeting, Feb 22, 2024.공시 • Nov 29Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability TestingOptimi Health Corp. has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, strengthening its position as a pioneering force in the psychedelic research and formulation space. Demonstrating its commitment to innovation and research, Optimi has cultivated these new Psilocybin-containing mushroom strains with the aim that they will play a pivotal role in the development of psilocybin extracts and novel drug candidates. Optimi also announces the advancement of its full spectrum, GMP extract quality program. The Company has successfully completed process validation for the natural psilocybin drug candidate, and the stability testing according to ICH guidelines is ongoing. With over three months of accelerated data, Optimi can confirm the product is able to maintain potency and other quality attributes for the duration of clinical trials. While Optimi continues to develop its product offerings, it remains focused on fulfilling supply orders, conducting tests, and analyzing the recent milestone harvest. The company announced the availability of GMP Psilocybin API for encapsulation into standardized dosages or for sale to other groups as a raw material for their formulations. This marks a significant step in expanding the company's reach and impact within the psychedelic research community.공시 • Nov 08Optimi Health Corp. Announces Executive ChangesOptimi Health Corp. announced the appointment of Dr. Preston A. Chase as the Company’s Chief Science Officer (CSO). Dr. Chase is a distinguished Research & Development chemist and seasoned business professional with an impressive academic and industrial track record spanning over 25 years. His extensive experience includes pioneering the development and commercialization of innovative products and processes for both multinational corporations and startup ventures. He holds a BSc from the University of Victoria and a PhD from the University of Calgary, and a solid foundation in catalysis, synthesis, and analytical chemistry. With over 30 peer-reviewed scientific publications and numerous awarded and pending patents, he brings a wealth of research expertise and a strong history of commercial success to the Optimi Health team. In his new role, Dr. Chase will take charge of shaping and advancing research capabilities and delivering safe, effective products to the nascent psychedelic market. His mandate includes the critical task of establishing the scientific validity and utility of Optimi's GMP psilocybin and MDMA drug candidates while fostering transparent communication with scientific and customer communities. He will also lead a core scientific team throughout the development process, ensuring that the Company continues to push the boundaries of innovation. Further, his experience in analysis of botanicals for medical use will support the integrity of Optimi’s drug candidates and the robustness of the Company’s supply pathway, ensuring that Optimi meets the higher standards of quality assurance and regulatory compliance in cultivation and dose factor for its customers. As Dr. Chase assumes leadership of Optimi's R&D and science-driven protocols, the Company extends its appreciation to Justin Kirkland, the departing CSO, for his devoted service to Optimi during the last two years. Mr. Kirkland will continue his association with the Company as a project consultant.공시 • Sep 15Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical TrialOptimi Health Corp. announced the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published on Nature Medicine. The Company considers the results to be a substantial step forward in the treatment of individuals grappling with moderate to severe Post-Traumatic Stress Disorder (PTSD). The study, conducted across multiple sites, showcases the potential of MDMA-AT to significantly reduce PTSD symptoms and functional impairment, indicating it as a promising therapeutic avenue. The randomized, double-blind, confirmatory Phase 3 study focused on the assessment of the efficacy and safety of MDMA-assisted therapy in comparison to placebo with identical therapy. This trial was notably diverse, including a significant representation from the Hispanic/Latino community (26.9%) and individuals identifying as other than White (33.7%), presenting a comprehensive insight into the therapy's effectiveness across a broad spectrum of individuals. Moreover, the participants undergoing MDMA-AT displayed a marked improvement in functionality, as measured by the Sheehan Disability Scale (SDS) functional impairment score, with a mean change of -3.3 compared to -2.1 in the placebo group, also showcasing statistical significance with P=0.03 and a moderate effect size (d=0.4). An encouraging aspect of the trial outcomes is the general tolerability of the treatment. While seven participants experienced a severe treatment emergent adverse event (TEAE), there were no deaths or serious TEAEs reported, emphasizing the general safety of the MDMA-AT approach. Optimi gratefully acknowledges the participants, clinicians, and all involved who have played a crucial role in bringing this pioneering study to fruition.공시 • May 11Natural Health Grants Optimi Health Corp. Product Site License by Health CanadaOptimi Health Corp. announced the receipt of its Natural Health Product Site License following an assessment by the Natural and Non-prescription Health Products Directorate. Under section 29 of the Natural Health Products Regulations, the expanded licensing allows for the manufacturing, packaging, and labelling of Natural Health Products (“NHPs”) at the Company’s Princeton, British Columbia facility. Further, the license also gives Optimi the ability to encapsulate products on site. Announcement affirms Optimi’s commitment to supplying large scale research and development programs through its 10,000 square foot GMP compliant manufacturing facility.공시 • Feb 08Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy TherapistsOptimi Health Corp. announced the submission of its clinical trial application (CTA) for a Phase I combinatorial study that will document the safety of Optimi’s natural psilocybin standardized extract and proprietary 3,4-methylenedioxy-methamphetamine (MDMA) drug candidate in healthy therapist subjects. Optimi announced the successful completion of its novel MDMA drug candidate, OPTI-MHCL, which was tested for purity on-site with a result of >99% over multiple consistent batches by Chief Science Officer, Justin Kirkland. Both drug candidates are scheduled to be administered in the clinical trial and will be manufactured in-house at Optimi’s 20,000 square foot facilities in Princeton, British Columbia. The investigator-initiated double-blind placebo-controlled study is being conducted through ATMA Journey Centers in Calgary, Alberta, and will be the first-of-its-kind to directly compare the acute effects of these substances within the same clinical study. ATMA is currently the only Canadian organization that has completed a successful Phase I safety trial with natural psilocybin in healthy therapists. The primary objective of the trial is to demonstrate the safety and tolerability of the combinatory use of natural psilocybin and MDMA in healthy participants, broadly validating Optimi’s offering and, in later stages, indicating the suitability for use of these substances, combined and separately, in experiential training by psychedelic therapy practitioners.공시 • Feb 07Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCLOptimi Health Corp. announced the completion of its proprietary preclinical MDMA drug candidate OPTI-MHCL for use in drug development, clinical trials, and individual patients authorized by Health Canada’s Special Access Program and Australia’s recently announced Authorized Prescriber Scheme. The production of OPTI-MHCL was made using the Company’s proprietary method and makes Optimi the only publicly listed psychedelics company licensed by Health Canada to possess, produce, assemble, sell, and supply its formulation in patient-ready encapsulated doses across global markets. OPTI-MHCL was manufactured in accordance with GMP protocols led by Chief Science Officer, Justin Kirkland, at the Company’s lab in Princeton, British Columbia and was validated after Kirkland achieved consistent results over multiple batches. In addition to on-site testing, Optimi submits all of its products to third-party laboratories for independent analysis to ensure the highest possible purity and suitability for OPTI-MHCL’s anticipated universal use. On September 22, 2022, Optimi and ATMA Journey Centers announced their intent to proceed with a Phase I clinical trial application (CTA) using Optimi’s natural psilocybin extract and MDMA. The goal of the trial is to support a pathway towards regulatory approval by establishing the safety and tolerability of both drug candidates on healthy patients. Optimi Health products are still being investigated through a clinically validated development program for the purpose of applying for market authorization.공시 • Jan 12Optimi Health Corp. Announces Departs Michael Stier as DirectorOptimi Health Corp. announced that departing of Mr. Michael Stier as director following the Company's Annual General Meeting held January 9, 2023.공시 • Nov 12Optimi Health Corp., Annual General Meeting, Jan 09, 2023Optimi Health Corp., Annual General Meeting, Jan 09, 2023.매출 및 비용 세부 내역Optimi Health가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:OPTH 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-43030 Sep 250-43030 Jun 251-43131 Mar 250-54131 Dec 241-64130 Sep 240-64030 Jun 240-64031 Mar 240-64031 Dec 230-54030 Sep 230-54030 Jun 230-64031 Mar 230-54031 Dec 220-65030 Sep 220-76030 Jun 220-87031 Mar 220-109031 Dec 210-97030 Sep 210-650양질의 수익: OPTH 은(는) 현재 수익성이 없습니다.이익 마진 증가: OPTH는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: OPTH는 수익성이 없지만 지난 5년 동안 연평균 15.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 OPTH의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: OPTH은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: OPTH는 현재 수익성이 없으므로 자본 수익률이 음수(-79.87%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 13:55종가2026/05/26 00:00수익2025/12/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Optimi Health Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • 21hOptimi Health Corp Advances Highest-Purity Natural Psilocybin ExtractOptimi Health Corp. announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical psilocybin extract produced by the Company to date. The milestone reflects sustained gains across Optimi's cultivation program. Drawing on a proprietary library of more than 200 distinct mushroom genetics maintained at the Company's facilities, Optimi has selectively advanced cultivars demonstrating increasingly elevated psilocybin content. Those cultivation improvements, combined with refinements to the Company's extraction process, have produced a botanical extract substantially more concentrated than prior production cycles while maintaining its naturally derived profile. A portion of the completed extract has been earmarked to support upcoming clinical research programs in Europe, where Optimi is expected to supply GMP-grade finished material into sponsor-led studies. Consistent with the Company's role as a regulated manufacturer rather than a drug-development sponsor, Optimi's contribution is the supply of psilocybin-containing finished drug products. Remaining biomass from the psilocybin production cycle will be retained at Optimi's facilities for ongoing product development, formulation refinement, and future regulated supply initiatives as international access pathways continue to expand. The milestone also reinforces Optimi's commercial supply in Australia, where the Company's naturally derived 5 mg psilocybin capsules are being prescribed for treatment-resistant depression under the Therapeutic Goods Administration's Authorised Prescriber Scheme. The higher-purity extract strengthens the material base supporting that supply. Optimi remains among a small number of commercial-stage companies worldwide whose psilocybin drug products are reaching patients through reimbursed treatment pathways, with eligible Australian patients accessing psilocybin-assisted therapy for treatment-resistant depression supported by established reimbursement initiatives. Aggregated data published in connection with Australia's Authorised Prescriber Scheme, under which Optimi has supplied psilocybin finished products since September 2025, indicate that no serious adverse events have been reported among patients treated with psilocybin under the Scheme as of December 2025.
New Risk • May 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 75% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Revenue is less than US$1m (CA$194k revenue, or US$141k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$33.5m market cap).
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Jason Mosberian was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 20Optimi Health Corp. has completed a Follow-on Equity Offering in the amount of $15 million.Optimi Health Corp. has completed a Follow-on Equity Offering in the amount of $15 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,400,000 Price\Range: $6.25 Discount Per Security: $0.47 Transaction Features: New Market Listing
공시 • Jan 27Optimi Health Completes First 2026 Production of MDMA and Psilocybin CapsulesOptimi Health Corp. reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 naturally derived psilocybin capsules in a 5 mg dosage form. Final packaging, labelling, and batch release were completed in accordance with Optimi's Drug Establishment Licence issued by Health Canada. The capsules are GMP-compliant and supported by Certificates of Analysis confirming conformance with applicable quality specifications, following receipt of the required Australian import permits. Post-Traumatic Stress Disorder (PTSD) and Treatment-Resistant Depression (TRD) represent significant unmet medical needs in Australia. National data published by the Australian Bureau of Statistics indicate that approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people. According to the Australian Institute of Health and Welfare, more than 1.3 million Australians are affected by depressive disorders, and clinical research suggests that around one-third of individuals with major depressive disorder do not respond adequately to standard treatments.
공시 • Dec 20Optimi Health Corp. Announces Board ChangesOptimi Health Corp. has appointed Mr. Jason Mosberian as a director of the Company, effective 18 December 2025. Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in public practice for 6 years. He currently serves as Senior Vice President and Partner at BFL Canada and has over a decade of experience providing tailored risk management and insurance solutions to clients in various industries, including manufacturing, distribution and life sciences. Mr. Mosberian replaces Mr. Jonathan Schintler on the Company's Board of Directors. Mr. Mosberian's appointment is subject to the approval of the Canadian Securities Exchange.
공시 • Sep 06Optimi Health Corp. has filed an IPO in the amount of $27.0125 million.Optimi Health Corp. has filed an IPO in the amount of $27.0125 million. Security Name: Common Shares Security Type: Common Stock
공시 • Jul 30Optimi Health Corp., Annual General Meeting, Sep 08, 2025Optimi Health Corp., Annual General Meeting, Sep 08, 2025. Location: unit 600, 21 water street, british columbia, v6b 1a1, vancouver Canada
공시 • Jul 20Optimi Health Corp. announced that it expects to receive CAD 3.45 million in fundingOptimi Health Corp. announces a non-brokered private placement to issue 3,450 unsecured convertible debentures at a price of CAD 1,000 per Convertible Debenture for gross proceeds of CAD 3,450,000 on July 18, 2025. The Convertible Debentures will bear interest at a rate of 15% per annum. The principal amount of each Convertible Debenture will be convertible into common shares of the Company at a conversion price of CAD 0.15, being the closing price of the Common Shares on the Canadian Securities Exchange preceding the execution by each Investor of the subscription agreement for the Convertible Debentures. All securities issued under the Offering, including securities issuable on conversion thereof, will be subject to a hold period expiring four months and a day from the date of issuance, in accordance with the rules and policies of the CSE and applicable Canadian securities laws. The Offering is expected to close on or about July 24, 2025
공시 • Mar 12Optimi Health Corp. announced a financing transactionOptimi Health Corp. announced a private placement that it will issue 100,000 common shares of the company at a deemed price per share to receive funding on March 12, 2025. The shares will be subject to a hold period of four months and one day from the date of issuance. Additionally, the Company is settling CAD 20,000 in outstanding service fees by issuing common shares at a deemed price per share equal to the closing price on the CSE on the last trading day prior to issuance. The transaction is expected to close on or around March 19, 2025.
공시 • Feb 01Optimi Health Corp. Completes Larger MDMA Capsule Batch to Date, Expands Stability ProgramOptimi Health Corp. has completed its larger production batch of MDMA to date—over 4,000 GMP capsules, enough to treat more than 1,000 patients. As part of its commitment to ensuring long-term product stability and quality, Optimi has also completed one year of stability data on previously manufactured MDMA capsules, validating a one-yearshelf life and extending the usability of its existing inventory for clinical and therapeutic applications. Additionally, the company has initiated a two-yearstability program to further validate the long-term quality and reliability of its MDMA capsules. With a growing number of authorized physicians prescribing Optimi's MDMA for PTSD in Australia, increasing demand for Special Access Program (SAP) requests in Canada, and a key Phase 2 clinical trial initiative for PTSD in Israel, Optimi is one of the few companies able to both manufacture its psychedelic drugs in-house and export cost-effective, GMP-grade MDMA capsules globally.
공시 • Jan 31Optimi Health Corp. Auditor Raises 'Going Concern' DoubtOptimi Health Corp. filed its Annual on Jan 29, 2025 for the period ending Sep 30, 2024. In this report its auditor, Davidson & Company, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
공시 • Jan 29Optimi Health Corp. announced that it has received CAD 0.9735 million in fundingOn January 28, 2025. Optimi Health Corp has closed the transaction. it has issued 1,316,668 Units at a price of CAD 0.30 per unit for gross proceeds of CAD 395,000.14 in its second tranche. total Offering raise to CAD 934,000.
공시 • Jan 16Optimi Health Corp. Reports First Patients Dosed in Landmark Natural Psilocybin Study in New ZealandOptimi Health Corp. announced that its natural psilocybin extract has been successfully exported to New Zealand. The shipment has enabled the dosing of the first participants using Optimi's natural psilocybin extract in a groundbreaking clinical trial supported by Tu Wairua, and the Matai Medical Research Institute, based in Gisborne, New Zealand. The study is the first of its kind, combining indigenous Maori knowledge systems (matauranga Maori) with cutting-edge clinical methodologies to address methamphetamine addiction. The inaugural cohort of participants has completed preparatory sessions and received psilocybin-assisted therapy in a culturally grounded, marae-based setting using Optimi's natural p silocybin extract. Key Highlights. First Participants Dosed: Optimi's natural psilocbin extract was administered to participants at Rangiwaho Marae, marking a historic step in combining traditional healing frameworks with modern therapeutic approaches. Innovative Collaboration. The Tu Wairua initiative unites indigenous leaders, health researchers, and industry partners, including Rua Bioscience and the Institute of Environmental Science and Research (ESR), to explore the therapeutic potential of taonga (mushroom) varieties. Cultural Integration. The trial emphasizes tikanga (cultural protocols) and collective reflection to ensure the safety, feasibility, and long-term well-being of participants and their communities. Supporting Indigenous Leadership in Psychedelic Therapies. Building a Framework for Global Psychedelic Innovation. The study, supported by Rua Bioscience and other New Zealand-based organizations, is a testament to the global collaboration required to advance psychedelic medicine responsibly. Optimi's involvement underscores the Company's mission to make high-quality, natural psilocybin accessible to researchers and patients worldwide. Learnings from this clinical trial will inform future trial phases and contribute to the broader understanding of psilocybin-assisted therapies.
공시 • Oct 24Optimi Health Corp. Announces First PTSD Patients Treated with MDMA Capsules in AustraliaOptimi Health Corp. announced that the first group of patients with post-traumatic stress disorder (PTSD) in Australia has successfully received treatment with its GMP-certified MDMA capsules under the Authorised Prescriber Scheme. In response to growing demand, the Company has received an additional order for 700 doses after its initial shipment of 160 doses was fully allocated in under eight weeks. First Patient Dosing: Patients in Australia are being treated with Optimi's GMP-certifiedMD capsules for PTSD, positioning Optimi as one of the few companies with in-market products actively treating real patients. Additional Orders: An additional 700 doses of MDMA capsules have been ordered to meet demand after the initial 160 doses were fully allocated in less than eight weeks. Real World Data: The Patient Reported Outcomes (PROs) being gathered through the patient registry at Australian National University will provide data on the effectiveness of MDMA treatments across a diverse range of Australian patients. The data collected from thousands of patients using Optimi's MDMA will be one of the most comprehensive and valuable data sets in the history of psychedelic-assisted therapies. Optimi's close collaboration with Mind Medicine Australia-a leading non-profit focused on expanding access to psychedelic-assisted therapies-has been instrumental in bringing these treatments to market. Mind Medicine Australia advocates for the safe integration of psychedelics into mental health treatments and has been a key partner in connecting Optimi's MDMA with Australian healthcare providers.
공시 • Oct 21Optimi Health Corp. Announces Chief Executive Officer ChangesOptimi Health Corp. announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons. Effective October 21, 2024, the Board has appointed Mr. Dane Stevens, Co-Founder of Optimi, as Interim Chief Executive Officer. In this role, Mr. Stevens will continue to advance the Company's key initiatives, with a focus on business development, expanding revenue opportunities, and maintaining the Company's strategic direction.
공시 • Aug 08Optimi Health Corp. announced that it expects to receive CAD 5 million in fundingOptimi Health Corp. announced a non brokered private placement of up to 16,666,666 units at an issue price of CAD 0.30 per unit for the gross proceeds of CAD 4,999,999.8 on August 7, 2024. Each Unit comprised of one common share and one-half of one transferable Common Share purchase warrant. Each Warrant entitles the holder to acquire one Common Share at CAD 0.40 for two years from the date of issuance. It is anticipated that insiders of the Company may participate in the Offering for up to CAD 500,000. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws. In connection with the Offering the Company may pay, to qualified non-related parties, a finder’s fee in cash equal to 4% of the gross proceeds raised.
공시 • May 15Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp CapsulesOptimi Health Corp. announced it has received a Certificate of Analysis (COA) from independent third-party laboratory testing, confirming that Optimi’s formulated MDMA meets Good Manufacturing Practice (GMP) specifications. Optimi has also completed GMP process validation for the encapsulation of the active pharmaceutical ingredient (API) in both 40mg and 60mg dosage formats for batch sizes up to 1,000 capsules during GMP production. The COA for the finished product affirms important data and analytics around content uniformity, microbial and water content, and dosage strength. Additionally, Optimi’s ongoing stability testing demonstrated that the MDMA API used to make both dosages remains stable within the capsules under both real-time and accelerated storage conditions for up to three months. The MDMA API used to produce the releasable GMP capsules has a purity level of 99.95%.
공시 • May 10Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic ResearchOptimi Health Corp. reported a significant update to its collaboration with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV. With the Export Permit confirmed, Optimi will be one of the first psychedelics pharmaceutical manufacturers to ship MDMA to the country.
공시 • Apr 16Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical IngredientOptimi Health Corp. has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence. Optimi employed the precursor 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) to guarantee the quality and uniformity of the MDMA API manufacturing process. The production of this MDMA API was produced in-house, explicitly for the recently disclosed supply agreement with the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel.
공시 • Apr 02Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin ExtractOptimi Health Corp. announced that three validation batches of its Natural Psilocybin Extract have undergone full release testing and have been issued the Certificate of Analysis (COA) by a third-party, confirming compliance with Good Manufacturing Practice (GMP) specifications. Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats. The third-party COA confirms critical information regarding potency, water content, microbial content, and heavy metal content, ensuring that the Natural Psilocybin Extract meets the predetermined specifications. The completion of both extract validation and finished product testing aligns with Optimi's goal of advancing the drug candidate, marking significant progress toward its eventual release for human consumption. After six months of accelerated data collection, Optimi confirms that its Natural Psilocybin Extract maintained its original potency level without any degradation during stability testing. Furthermore, the Psilocybe cubensis mushrooms used in creating the extract were cultivated in-house under Good Agricultural Collection Practice (GACP) conditions. As the Company prepares to meet its Australian supply commitments with Mind Medicine Australia, Karina Lahnakoski, Optimi's Director of Quality and Commercial Strategies, assures patients and therapists of the reliability and quality of Optimi's drug candidates. Dedicated to fostering collaborations and advancing the scientific understanding of the potential therapeutic benefits of psilocybin, Optimi welcomes inquiries from principal investigators and research groups interested in learning more about the Company’s validated GMP Natural Psilocybin Extract and other drug candidates.
공시 • Feb 10Optimi Health Corp. announced that it expects to receive CAD 1.5 million in fundingOptimi Health Corp announces non-brokered private placement of 5,000,000 units at an issue price of CAD 0.30 per Unit for gross proceeds of CAD 1,500,000 on February 8, 2024. Each unit consists of one common share and one half of one transferable Common Share purchase warrant. Each Warrant entitles the holder to acquire one (1) Common Share at CAD 0.40 for two (2) years from the date of issuance. the transaction include participation from insiders for CAD 605,000. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.
공시 • Dec 23Optimi Health Corp., Annual General Meeting, Feb 22, 2024Optimi Health Corp., Annual General Meeting, Feb 22, 2024.
공시 • Nov 29Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability TestingOptimi Health Corp. has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, strengthening its position as a pioneering force in the psychedelic research and formulation space. Demonstrating its commitment to innovation and research, Optimi has cultivated these new Psilocybin-containing mushroom strains with the aim that they will play a pivotal role in the development of psilocybin extracts and novel drug candidates. Optimi also announces the advancement of its full spectrum, GMP extract quality program. The Company has successfully completed process validation for the natural psilocybin drug candidate, and the stability testing according to ICH guidelines is ongoing. With over three months of accelerated data, Optimi can confirm the product is able to maintain potency and other quality attributes for the duration of clinical trials. While Optimi continues to develop its product offerings, it remains focused on fulfilling supply orders, conducting tests, and analyzing the recent milestone harvest. The company announced the availability of GMP Psilocybin API for encapsulation into standardized dosages or for sale to other groups as a raw material for their formulations. This marks a significant step in expanding the company's reach and impact within the psychedelic research community.
공시 • Nov 08Optimi Health Corp. Announces Executive ChangesOptimi Health Corp. announced the appointment of Dr. Preston A. Chase as the Company’s Chief Science Officer (CSO). Dr. Chase is a distinguished Research & Development chemist and seasoned business professional with an impressive academic and industrial track record spanning over 25 years. His extensive experience includes pioneering the development and commercialization of innovative products and processes for both multinational corporations and startup ventures. He holds a BSc from the University of Victoria and a PhD from the University of Calgary, and a solid foundation in catalysis, synthesis, and analytical chemistry. With over 30 peer-reviewed scientific publications and numerous awarded and pending patents, he brings a wealth of research expertise and a strong history of commercial success to the Optimi Health team. In his new role, Dr. Chase will take charge of shaping and advancing research capabilities and delivering safe, effective products to the nascent psychedelic market. His mandate includes the critical task of establishing the scientific validity and utility of Optimi's GMP psilocybin and MDMA drug candidates while fostering transparent communication with scientific and customer communities. He will also lead a core scientific team throughout the development process, ensuring that the Company continues to push the boundaries of innovation. Further, his experience in analysis of botanicals for medical use will support the integrity of Optimi’s drug candidates and the robustness of the Company’s supply pathway, ensuring that Optimi meets the higher standards of quality assurance and regulatory compliance in cultivation and dose factor for its customers. As Dr. Chase assumes leadership of Optimi's R&D and science-driven protocols, the Company extends its appreciation to Justin Kirkland, the departing CSO, for his devoted service to Optimi during the last two years. Mr. Kirkland will continue his association with the Company as a project consultant.
공시 • Sep 15Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical TrialOptimi Health Corp. announced the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published on Nature Medicine. The Company considers the results to be a substantial step forward in the treatment of individuals grappling with moderate to severe Post-Traumatic Stress Disorder (PTSD). The study, conducted across multiple sites, showcases the potential of MDMA-AT to significantly reduce PTSD symptoms and functional impairment, indicating it as a promising therapeutic avenue. The randomized, double-blind, confirmatory Phase 3 study focused on the assessment of the efficacy and safety of MDMA-assisted therapy in comparison to placebo with identical therapy. This trial was notably diverse, including a significant representation from the Hispanic/Latino community (26.9%) and individuals identifying as other than White (33.7%), presenting a comprehensive insight into the therapy's effectiveness across a broad spectrum of individuals. Moreover, the participants undergoing MDMA-AT displayed a marked improvement in functionality, as measured by the Sheehan Disability Scale (SDS) functional impairment score, with a mean change of -3.3 compared to -2.1 in the placebo group, also showcasing statistical significance with P=0.03 and a moderate effect size (d=0.4). An encouraging aspect of the trial outcomes is the general tolerability of the treatment. While seven participants experienced a severe treatment emergent adverse event (TEAE), there were no deaths or serious TEAEs reported, emphasizing the general safety of the MDMA-AT approach. Optimi gratefully acknowledges the participants, clinicians, and all involved who have played a crucial role in bringing this pioneering study to fruition.
공시 • May 11Natural Health Grants Optimi Health Corp. Product Site License by Health CanadaOptimi Health Corp. announced the receipt of its Natural Health Product Site License following an assessment by the Natural and Non-prescription Health Products Directorate. Under section 29 of the Natural Health Products Regulations, the expanded licensing allows for the manufacturing, packaging, and labelling of Natural Health Products (“NHPs”) at the Company’s Princeton, British Columbia facility. Further, the license also gives Optimi the ability to encapsulate products on site. Announcement affirms Optimi’s commitment to supplying large scale research and development programs through its 10,000 square foot GMP compliant manufacturing facility.
공시 • Feb 08Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy TherapistsOptimi Health Corp. announced the submission of its clinical trial application (CTA) for a Phase I combinatorial study that will document the safety of Optimi’s natural psilocybin standardized extract and proprietary 3,4-methylenedioxy-methamphetamine (MDMA) drug candidate in healthy therapist subjects. Optimi announced the successful completion of its novel MDMA drug candidate, OPTI-MHCL, which was tested for purity on-site with a result of >99% over multiple consistent batches by Chief Science Officer, Justin Kirkland. Both drug candidates are scheduled to be administered in the clinical trial and will be manufactured in-house at Optimi’s 20,000 square foot facilities in Princeton, British Columbia. The investigator-initiated double-blind placebo-controlled study is being conducted through ATMA Journey Centers in Calgary, Alberta, and will be the first-of-its-kind to directly compare the acute effects of these substances within the same clinical study. ATMA is currently the only Canadian organization that has completed a successful Phase I safety trial with natural psilocybin in healthy therapists. The primary objective of the trial is to demonstrate the safety and tolerability of the combinatory use of natural psilocybin and MDMA in healthy participants, broadly validating Optimi’s offering and, in later stages, indicating the suitability for use of these substances, combined and separately, in experiential training by psychedelic therapy practitioners.
공시 • Feb 07Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCLOptimi Health Corp. announced the completion of its proprietary preclinical MDMA drug candidate OPTI-MHCL for use in drug development, clinical trials, and individual patients authorized by Health Canada’s Special Access Program and Australia’s recently announced Authorized Prescriber Scheme. The production of OPTI-MHCL was made using the Company’s proprietary method and makes Optimi the only publicly listed psychedelics company licensed by Health Canada to possess, produce, assemble, sell, and supply its formulation in patient-ready encapsulated doses across global markets. OPTI-MHCL was manufactured in accordance with GMP protocols led by Chief Science Officer, Justin Kirkland, at the Company’s lab in Princeton, British Columbia and was validated after Kirkland achieved consistent results over multiple batches. In addition to on-site testing, Optimi submits all of its products to third-party laboratories for independent analysis to ensure the highest possible purity and suitability for OPTI-MHCL’s anticipated universal use. On September 22, 2022, Optimi and ATMA Journey Centers announced their intent to proceed with a Phase I clinical trial application (CTA) using Optimi’s natural psilocybin extract and MDMA. The goal of the trial is to support a pathway towards regulatory approval by establishing the safety and tolerability of both drug candidates on healthy patients. Optimi Health products are still being investigated through a clinically validated development program for the purpose of applying for market authorization.
공시 • Jan 12Optimi Health Corp. Announces Departs Michael Stier as DirectorOptimi Health Corp. announced that departing of Mr. Michael Stier as director following the Company's Annual General Meeting held January 9, 2023.
공시 • Nov 12Optimi Health Corp., Annual General Meeting, Jan 09, 2023Optimi Health Corp., Annual General Meeting, Jan 09, 2023.